Company intelligence / Profile preview

Nanjing Denovo Pharmaceutical Technology

Nanjing, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Nanjing Denovo Pharmaceutical Technology is a China-based biotechnology company focused on the research and development of innovative small molecule drugs, particularly for the treatment of chronic infectious diseases. The company's lead program is focused on developing highly potent and safe treatments for chronic Hepatitis B (HBV). By leveraging its expertise in medicinal chemistry and antiviral drug design, Nanjing Denovo aims to provide functional cures for patients suffering from viral hepatitis. The company operates primarily out of the Nanjing Jiangbei New Area, a major hub for life sciences in China.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Nanjing Denovo Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanjing Denovo Pharmaceutical Technology.

Explore the full profile